Core Viewpoint - Zenas BioPharma, Inc. is facing a class action lawsuit due to allegations of misleading information in its IPO registration statement, particularly regarding the funding timeline for its operations [1][3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit, titled Buathongsri v. Zenas BioPharma, Inc., allows purchasers of Zenas BioPharma securities from its IPO on September 13, 2024, to seek lead plaintiff status by June 16, 2025 [1][2]. - The lawsuit claims that Zenas BioPharma overstated its operational funding timeline, stating it could fund operations for 24 months instead of the actual 12 months disclosed later [3][4]. - As of April 15, 2025, Zenas BioPharma's stock closed at 17.00 per share [4]. Group 2: Company Background - Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing immunology-based therapies [2]. - The company sold over 13 million shares during its IPO at a price of 17.00 per share [2]. Group 3: Legal Representation - Robbins Geller Rudman & Dowd LLP is representing investors in this class action lawsuit and is recognized as a leading law firm in securities fraud litigation [6]. - The firm has a strong track record, having recovered over 2.5 billion for investors in 2024 alone [6].
ZBIO INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit